VG H&N course intro Florence 2016.pptx

474-475 / 2351

DAHANCA19 ‐ Acute morbidity
Confluent mucositis Grade 3‐4 in‐field reaction
itis (%)
60
zalutumumab
3+4 (%)
60
Maximum difference at day14 after
end of RT: p<0.0001
uent mucos
40
Control
ield grade
40
al t m mab
ntage confl
20
entage in-f0
20
z u u u
W1 W2 W3 W4 W5 End RT 14 day 2 month
Perce
0
W1 W2 W3 W4 W5 End 2Wk 2Mo
Maximum difference in week 5: p=0.001
W1 W2 W3 W4 W5 End RT 14 day 2 months
Perc
W1 W2 W3 W4 W5 End 2Wk 2Mo
control
Need for tube‐feeding at end of treatment:
No difference (50% vs. 50%)
Eriksen, H&N Arizona 2014